Our recent work showed that plasma levels of HMGB1 increased after the onset of IS, and inhibition of HMGB1 activity via administration of a recombinant-soluble form of receptor for advanced glycation end-products significantly improved outcome in a mouse stroke model [36]. The gene discussed is HMGB1; the disease is stroke disorder.